Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Consolidated Net Income fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.9 million, marking a year-over-year decrease of 20228.73%. This contributed to the annual value of -$376.8 million for FY2024, which is 18424.88% down from last year.
  • As of Q3 2025, Beam Therapeutics' Consolidated Net Income stood at -$112.7 million, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • Beam Therapeutics' Consolidated Net Income's 5-year high stood at $142.8 million during Q4 2023, with a 5-year trough of -$200.4 million in Q1 2021.
  • Its 5-year average for Consolidated Net Income is -$76.3 million, with a median of -$89.0 million in 2023.
  • As far as peak fluctuations go, Beam Therapeutics' Consolidated Net Income plummeted by 62193.24% in 2021, and later surged by 47227.31% in 2023.
  • Over the past 5 years, Beam Therapeutics' Consolidated Net Income (Quarter) stood at -$64.7 million in 2021, then surged by 40.73% to -$38.3 million in 2022, then skyrocketed by 472.27% to $142.8 million in 2023, then crashed by 163.33% to -$90.4 million in 2024, then dropped by 24.68% to -$112.7 million in 2025.
  • Its Consolidated Net Income stands at -$112.7 million for Q3 2025, versus -$102.3 million for Q2 2025 and -$109.4 million for Q1 2025.